ArticleOncotarget2018
Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Systematic review and meta-analysis of the clinical features of MGRS.BMC nephrology · 2024Pooled it
- Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance.Blood advances · 2026Article
- Monoclonal gammopathy of clinical significance: a multisystem review.Blood cancer journal · 2026Review
- Article
- Clinical predictors of monoclonal gammopathy of renal significance: a multicenter study in Japan.Clinical and experimental nephrology · 2026Article
- The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy.Kidney international · 2025Article
- Progression of IgM Monoclonal Gammopathy of Renal Significance (MGRS) to Symptomatic Waldenström Macroglobulinemia: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- Quantitative risk of underlying disease conditions for progression from monoclonal gammopathy to multiple myeloma: a nationwide cohort study.ESMO open · 2025Article
- Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies.Clinical and experimental medicine · 2025Article
- Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran.Iranian journal of medical sciences · 2024Article
- Development and validation of a diagnostic nomogram model for predicting monoclonal gammopathy of renal significance.Scientific reports · 2024Article
- Unusual Cases of Monoclonal Gammopathy of Renal Significance.Case reports in nephrology · 2024Article
- Monoclonal gammopathy of increasing significance: time to screen?Haematologica · 2023Review
- Rhabdomyolysis and Acute Renal Dysfunction as Initial Manifestations of Monoclonal Gammopathy of Renal Significance.Cureus · 2023Article
- Monoclonal Gammopathy of Renal Significance: A Molecular Middle Earth between Oncology, Nephrology, and Pathology.Kidney diseases (Basel, Switzerland) · 2022Review
- Review
- Histological Findings in Kidney Biopsies of Patients with Monoclonal Gammopathy-Always a Surprise.Diagnostics (Basel, Switzerland) · 2022Article
- Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.American journal of hematology · 2022Article
- Monoclonal Gammopathy of Renal Significance: Histomorphological Spectrum at a Tertiary Care Center.Glomerular diseases · 2022Article
- Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMonoclonal gammopathy of undetermined significance (MGUS) is a premalignancy preceding multiple myeloma (MM) or related disorders. In MGUS, renal impairment caused by deposition of the monoclonal immunoglobulins or free light-chains monoclonal gammopathy of renal significance (MGRS) is often associated with high morbidity and mortality. We analysed the prevalence of renal impairment, clinical features and the long-term outcome in 2935 patients with MGUS.
methodsBetween 1/2000 and 8/2016, 2935 adult patients with MGUS were identified in our database.
resultsIn 44/2935 (1.5%) patients MGRS was diagnosed. In MGRS patients, significantly more progressions to MM were observed than in MGUS patients (18% vs. 3%; P<0.001). MGRS patients showed a higher risk for progression (HR 3.3 [1.5-7.4]) in the Cox model. Median time to progression was 23 years for MGUS and 18.8 years for MGRS patients. Corresponding progression rate was 8.8 [7.2-10.7] per 1000 patient-years (py) for MGUS patients and 30.6 [15.3-61] for the MGRS group. Risk for progression within the first year after diagnosis was 1% [0.6-1.4] in the MGUS group and 10% [4-29] among MGRS patients.
conclusionThe significantly higher risk for progression to MM means MGRS patients should be monitored carefully and treated in a specialized centre.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.